{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T18:26:18Z","timestamp":1662229578747},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00120-021-01573-x","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T10:02:56Z","timestamp":1625652176000},"page":"847-853","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hodentumor und Peniskarzinom\u00a0\u2013 \u00dcberleben mit Lebensqualit\u00e4t"],"prefix":"10.1007","volume":"60","author":[{"given":"S.","family":"Krege","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Protzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"1573_CR1","unstructured":"S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens Langversion 1.1 \u2013 Feb. 2020, AWMF-Registernummer 043\/049OL"},{"key":"1573_CR2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.18.01480","volume":"37","author":"KP Dieckmann","year":"2019","unstructured":"Dieckmann\u00a0KP, Radtke\u00a0A, Geczi\u00a0L et al (2019) Serum levels of microRNA-371a-3p (M371 test) as a\u00a0new biomarker of testicular germ cell tumors: results of a\u00a0prospective multicentric study. J\u00a0Clin Oncol 37:1412","journal-title":"J Clin Oncol"},{"key":"1573_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/MOU.0000000000000726","volume":"30","author":"L Nappi","year":"2020","unstructured":"Nappi\u00a0L, Kollmannsberger\u00a0C, Nichols\u00a0C (2020) The role of micro-RNAs in the management of germ cell tumors: future directions. Curr Opin Urol 30:258\u2013263","journal-title":"Curr Opin Urol"},{"key":"1573_CR4","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","volume":"27","author":"T Tandstad","year":"2009","unstructured":"Tandstad\u00a0T, Dahl\u00a0O, Cohn-Cedermark\u00a0G et al (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J\u00a0Clin Oncol 27:2122\u20132128","journal-title":"J Clin Oncol"},{"key":"1573_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.eururo.2010.12.010","volume":"59","author":"JF Sturgeon","year":"2011","unstructured":"Sturgeon\u00a0JF, Moore\u00a0MJ, Kakiashvili\u00a0DM et al (2011) Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital`s experience. Eur Urol 59:556\u2013562","journal-title":"Eur Urol"},{"key":"1573_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","volume":"33","author":"C Kollmannsberger","year":"2015","unstructured":"Kollmannsberger\u00a0C, Tandstad\u00a0T, Bedard\u00a0PL et\u00a0al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J\u00a0Clin Oncol 33:51\u201357","journal-title":"J Clin Oncol"},{"key":"1573_CR7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/annonc\/mdu375","volume":"25","author":"T Tandstad","year":"2014","unstructured":"Tandstad\u00a0T, Stahl\u00a0O, Hakansson\u00a0U et\u00a0al (2014) One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 25:2167\u20132172","journal-title":"Ann Oncol"},{"key":"1573_CR8","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2002.01.038","volume":"20","author":"P Warde","year":"2002","unstructured":"Warde\u00a0P, Specht\u00a0L, Horwich\u00a0A et\u00a0al (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a\u00a0pooled analysis. J\u00a0Clin Oncol 20:4448\u20134452","journal-title":"J Clin Oncol"},{"key":"1573_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.eururo.2017.09.025","volume":"73","author":"JL Boormans","year":"2018","unstructured":"Boormans\u00a0JL, Mayor de Castro\u00a0J, Marconi\u00a0L et\u00a0al (2018) Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a\u00a0systematic review by the Testicular Cancer Guidelines Panel. Eur Urol 73:394\u2013405","journal-title":"Eur Urol"},{"key":"1573_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.urolonc.2017.06.047","volume":"36","author":"F Zengerling","year":"2018","unstructured":"Zengerling\u00a0F, Kunath\u00a0F, Jensen\u00a0K et\u00a0al (2018) Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance \u2013 a\u00a0systematic review. Urol Oncol 36:448\u2013458","journal-title":"Urol Oncol"},{"key":"1573_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(05)66984-X","volume":"366","author":"RT Oliver","year":"2005","unstructured":"Oliver\u00a0RT, Mason\u00a0MD, Mead\u00a0GM et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a\u00a0randomised trial. Lancet 366:293\u2013300","journal-title":"Lancet"},{"key":"1573_CR12","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/annonc\/mdw164","volume":"27","author":"T Tandstad","year":"2016","unstructured":"Tandstad\u00a0T, Stahl\u00a0O, Dahl\u00a0O et al (2016) Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a\u00a0report from the Swedish and Norwegian Testicular Cancer group (SWENOTECA). Ann Oncol 27:1299\u20131304","journal-title":"Ann Oncol"},{"key":"1573_CR13","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/annonc\/mdu437","volume":"25","author":"J Aparicio","year":"2014","unstructured":"Aparicio\u00a0J, Maroto\u00a0P, Garcia del Muro\u00a0X et al (2014) Prognostic factors for relapse in stage I seminoma: a\u00a0new nomogram derived from three consecurive, risk-adapted studies from the Spanish Germ Cell Cancer group (SGCCG). Ann Oncol 25:2173\u20132178","journal-title":"Ann Oncol"},{"key":"1573_CR14","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1200\/JCO.2007.12.0808","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson\u00a0AJ, Bosl\u00a0GJ, Motzer\u00a0RJ et\u00a0al (2007) Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J\u00a0Clin Oncol 25:5597\u20135602","journal-title":"J Clin Oncol"},{"key":"1573_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/01.ju.0000165163.03805.37","volume":"174","author":"AJ Stephenson","year":"2005","unstructured":"Stephenson\u00a0AJ, Bosl\u00a0GJ, Bajorin\u00a0DF et\u00a0al (2005) Retroperitoneal lymh node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and\/or lymphivascular invasion. J\u00a0Urol 174:557\u2013560","journal-title":"J Urol"},{"key":"1573_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.2004.07.178","volume":"22","author":"GV Kondagunta","year":"2004","unstructured":"Kondagunta\u00a0GV, Sheinfeld\u00a0J, Mazumdar\u00a0M et\u00a0al (2004) Relapse free and overall survival in patients with pathological stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J\u00a0Clin Oncol 22:464\u2013467","journal-title":"J Clin Oncol"},{"key":"1573_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2013.551","volume":"110","author":"A Horwich","year":"2014","unstructured":"Horwich\u00a0A, Fossa\u00a0SD, Huddart\u00a0R et\u00a0al (2014) Second cancer risk and mortlity in men treated with radiotherapy for stage I seminoma. Br J Cancer 110:256\u2013263","journal-title":"Br J Cancer"},{"key":"1573_CR18","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","volume":"28","author":"HS Haugnes","year":"2010","unstructured":"Haugnes\u00a0HS, Wethal\u00a0T, Aass\u00a0N et al (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a\u00a020-year. J\u00a0Clin Oncol 28:4649\u20134657","journal-title":"J Clin Oncol"},{"key":"1573_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/0284186X.2020.1724328","volume":"59","author":"RV Nome","year":"2020","unstructured":"Nome\u00a0RV, Cvancarova Samstuen\u00a0M, Bjoro\u00a0T et\u00a0al (2020) Longitudinal kidney function outcome in aging testicular cancer survivors. Acta Oncol 59:467\u2013474","journal-title":"Acta Oncol"},{"key":"1573_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/annonc\/mds527","volume":"24","author":"EC de Haas","year":"2013","unstructured":"de Haas\u00a0EC, Altena\u00a0R, Boezen\u00a0HM et\u00a0al (2013) Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 24:749\u2013755","journal-title":"Ann Oncol"},{"key":"1573_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","volume":"15","author":"IGCCCG","year":"1997","unstructured":"IGCCCG (1997) International Germ Cell Consensus Classification: a\u00a0prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J\u00a0Clin Oncol 15:594\u2013603","journal-title":"J Clin Oncol"},{"key":"1573_CR22","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/cncr.10440","volume":"94","author":"WF Hendry","year":"2002","unstructured":"Hendry\u00a0WF, Norman\u00a0AR, Dearnaley\u00a0DP et\u00a0al (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94:1668\u20131676","journal-title":"Cancer"},{"key":"1573_CR23","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1200\/JCO.2007.11.2078","volume":"25","author":"BS Carver","year":"2007","unstructured":"Carver\u00a0BS, Shayegan\u00a0B, Eggener\u00a0S et\u00a0al (2007) Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a\u00a0modified postchemotherapy retroperitoneal lymph node dissection. J\u00a0Clin Oncol 25:4365\u20134369","journal-title":"J Clin Oncol"},{"key":"1573_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdm472","volume":"19","author":"K Fizazi","year":"2008","unstructured":"Fizazi\u00a0K, Oldenburg\u00a0J, Dunant\u00a0A et al (2008) Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 19:259\u2013264","journal-title":"Ann Oncol"},{"key":"1573_CR25","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.7314\/APJCP.2014.15.8.3525","volume":"15","author":"JY Zhao","year":"2014","unstructured":"Zhao\u00a0JY, Ma\u00a0XL, Li\u00a0YY et al (2014) Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a\u00a0meta-analysis. Asian Pac J Cancer Prev 15:3525\u20133531","journal-title":"Asian Pac J Cancer Prev"},{"key":"1573_CR26","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) S3-Leitlinie Diagnostik, Therapie und Nachsorge des Peniskarzinoms, Langversion 1.0, 2020, AWMF Registernummer:043-042OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/peniskarzinom\/"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01573-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01573-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01573-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T12:16:55Z","timestamp":1626178615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01573-x"}},"subtitle":["Neue Leitlinien und Zweitmeinungsnetzwerk"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01573-x","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"21 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Krege und C.\u00a0Protzel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}